Actavis PLC said Friday that it is seeking approval from the U.S. Food and Drug Administration to sell a generic version of Gilead Sciences Inc.’s pulmonary arterial hypertension treatment.
from WSJ.com: US Business http://ift.tt/1Ck2ybw
via IFTTT
from WSJ.com: US Business http://ift.tt/1Ck2ybw
via IFTTT
No comments:
Post a Comment